Perez-Mancera, P. A., Young, A. R., & Narita, M. (2014). Inside and out: The activities of senescence in cancer. Nature Reviews Cancer, 14(8), 547–558. https://doi.org/10.1038/nrc3773
Herranz, N., & Gil, J. (2018). Mechanisms and functions of cellular senescence. The Journal of Clinical Investigation, 128(4), 1238–1246. https://doi.org/10.1172/JCI95148
Roninson, I. B. (2003). Tumor cell senescence in cancer treatment. Cancer Research, 63(11), 2705–2715.
Hayflick, L. (1965). The limited in vitro lifetime of human diploid cell strains. Experimental Cell Research, 37, 614–636.
Chang, B. D., Broude, E. V., Dokmanovic, M., Zhu, H., Ruth, A., Xuan, Y., et al. (1999). A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Research, 59(15), 3761–3767.
Shay, J. W., & Roninson, I. B. (2004). Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene, 23(16), 2919–2933. https://doi.org/10.1038/sj.onc.1207518
Collado, M., & Serrano, M. (2010). Senescence in tumours: evidence from mice and humans. Nature Reviews Cancer, 10(1), 51–57, nrc2772 [pii] https://doi.org/10.1038/nrc2772.
Jackson, J. G., Post, S. M., & Lozano, G. (2011). Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. The Journal of Pathology, 223(2), 127–136. https://doi.org/10.1002/path.2783
Smith, J. R., & Pereira-Smith, O. M. (1996). Replicative senescence: Implications for in vivo aging and tumor suppression. Science, 273(5271), 63–67.
Ruhland, M. K., Coussens, L. M., & Stewart, S. A. (2016). Senescence and cancer: An evolving inflammatory paradox. Biochimica et Biophysica Acta, 1865(1), 14–22. https://doi.org/10.1016/j.bbcan.2015.10.001
Tonnessen-Murray, C., Ungerleider, N. A., Rao, S. G., Wasylishen, A. R., Frey, W. D., & Jackson, J. G. (2018). p53 Mediates Vast Gene Expression Changes That Contribute to Poor Chemotherapeutic Response in a Mouse Model of Breast Cancer. Translational Oncology, 11(4), 930–940. https://doi.org/10.1016/j.tranon.2018.05.003
Rao, S. G., & Jackson, J. G. (2016). SASP: Tumor Suppressor or Promoter? Yes! Trends in Cancer, 2(11), 676–687. https://doi.org/10.1016/j.trecan.2016.10.001
Wiley, C. D., Sharma, R., Davis, S. S., Lopez-Dominguez, J. A., Mitchell, K. P., Wiley, S., et al. (2021). Oxylipin biosynthesis reinforces cellular senescence and allows detection of senolysis. Cell Metab, 33(6), 1124-1136 e1125. https://doi.org/10.1016/j.cmet.2021.03.008
Tonnessen-Murray, C., Lozano, G., & Jackson, J. G. (2016). The p53 Protein: From Cell Regulation to Cancer. In G. Lozano, & A. J. Levine (Eds.), The p53 Protein: From Cell Regulation to Cancer (pp. 173–186, A Cold Spring Harbor Perspectives in Medicine Collection). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
Jackson, J. G., Pant, V., Li, Q., Chang, L. L., Quintas-Cardama, A., Garza, D., et al. (2012). p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer. Cancer Cell, 21(6), 793–806. https://doi.org/10.1016/j.ccr.2012.04.027
Bertheau, P., Plassa, F., Espie, M., Turpin, E., de Roquancourt, A., Marty, M., et al. (2002). Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet, 360(9336), 852–854, S0140–6736(02)09969–5 [pii] https://doi.org/10.1016/S0140-6736(02)09969-5.
Wang, Y., Xu, Y., Chen, J., Ouyang, T., Li, J., Wang, T., et al. (2016). TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer. International Journal of Cancer, 138(2), 489–496. https://doi.org/10.1002/ijc.29715
Chen, M. B., Zhu, Y. Q., Xu, J. Y., Wang, L. Q., Liu, C. Y., Ji, Z. Y., et al. (2012). Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. PLoS One, 7(6), e39655. https://doi.org/10.1371/journal.pone.0039655
Esserman, L. J., Berry, D. A., Cheang, M. C., Yau, C., Perou, C. M., Carey, L., et al. (2012). Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Research and Treatment, 132(3), 1049–1062. https://doi.org/10.1007/s10549-011-1895-2
Ungerleider, N. A., Rao, S. G., Shahbandi, A., Yee, D., Niu, T., Frey, W. D., et al. (2018). Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. Breast Cancer Research, 20(1), 115. https://doi.org/10.1186/s13058-018-1044-5
Shahbandi, A., Nguyen, H. D., & Jackson, J. G. (2020). TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines. Trends Cancer, 6(2), 98–110. https://doi.org/10.1016/j.trecan.2020.01.007
De Blander, H., Morel, A. P., Senaratne, A. P., Ouzounova, M., & Puisieux, A. (2021). Cellular Plasticity: A Route to Senescence Exit and Tumorigenesis. Cancers (Basel), 13(18), https://doi.org/10.3390/cancers13184561.
Zhu, P., Zhang, C., Gao, Y., Wu, F., Zhou, Y., & Wu, W. S. (2019). The transcription factor Slug represses p16(Ink4a) and regulates murine muscle stem cell aging. Nature Communications, 10(1), 2568. https://doi.org/10.1038/s41467-019-10479-4
Nassour, J., Martien, S., Martin, N., Deruy, E., Tomellini, E., Malaquin, N., et al. (2016). Defective DNA single-strand break repair is responsible for senescence and neoplastic escape of epithelial cells. Nature Communications, 7, 10399. https://doi.org/10.1038/ncomms10399
Beausejour, C. M., Krtolica, A., Galimi, F., Narita, M., Lowe, S. W., Yaswen, P., et al. (2003). Reversal of human cellular senescence: Roles of the p53 and p16 pathways. EMBO Journal, 22(16), 4212–4222. https://doi.org/10.1093/emboj/cdg417
Roberson, R. S., Kussick, S. J., Vallieres, E., Chen, S. Y., & Wu, D. Y. (2005). Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Research, 65(7), 2795–2803. https://doi.org/10.1158/0008-5472.CAN-04-1270
Camorani, S., Cerchia, L., Fedele, M., Erba, E., D’Incalci, M., & Crescenzi, E. (2018). Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-kappaB. Oncotarget, 9(28), 19929–19944. https://doi.org/10.18632/oncotarget.24961
Olszewska, A., Borkowska, A., Granica, M., Karolczak, J., Zglinicki, B., Kieda, C., et al. (2021). Escape From Cisplatin-Induced Senescence of Hypoxic Lung Cancer Cells Can Be Overcome by Hydroxychloroquine. Front Oncol, 11, 738385. https://doi.org/10.3389/fonc.2021.738385
Chakradeo, S., Elmore, L. W., & Gewirtz, D. A. (2016). Is Senescence Reversible? Current Drug Targets, 17(4), 460–466. https://doi.org/10.2174/1389450116666150825113500
Duy, C., Li, M., Teater, M., Meydan, C., Garrett-Bakelman, F. E., Lee, T. C., et al. (2021). Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence. Cancer Discovery, 11(6), 1542–1561. https://doi.org/10.1158/2159-8290.CD-20-1375
Saleh, T., Tyutyunyk-Massey, L., Murray, G. F., Alotaibi, M. R., Kawale, A. S., Elsayed, Z., et al. (2019). Tumor cell escape from therapy-induced senescence. Biochemical Pharmacology, 162, 202–212. https://doi.org/10.1016/j.bcp.2018.12.013
Huang, B., Deo, D., Xia, M., & Vassilev, L. T. (2009). Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells. Molecular cancer research : MCR, 7(9), 1497–1509. https://doi.org/10.1158/1541-7786.MCR-09-0144
Rehman, S. K., Haynes, J., Collignon, E., Brown, K. R., Wang, Y., Nixon, A. M. L., et al. (2021). Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy. Cell, 184(1), 226-242.e221. https://doi.org/10.1016/j.cell.2020.11.018
Dhimolea, E., de Matos Simoes, R., Kansara, D., Al’Khafaji, A., Bouyssou, J., Weng, X., et al. (2021). An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. Cancer Cell, 39(2), 240-256.e211. https://doi.org/10.1016/j.ccell.2020.12.002
Endo, H., & Inoue, M. (2019). Dormancy in cancer. Cancer Science, 110(2), 474–480. https://doi.org/10.1111/cas.13917
Aguirre-Ghiso, J. A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews Cancer, 7(11), 834–846. https://doi.org/10.1038/nrc2256
Santos-de-Frutos, K., & Djouder, N. (2021). When dormancy fuels tumour relapse. Commun Biol, 4(1), 747. https://doi.org/10.1038/s42003-021-02257-0
Tonnessen-Murray, C. A., Frey, W. D., Rao, S. G., Shahbandi, A., Ungerleider, N. A., Olayiwola, J. O., et al. (2019). Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival. Journal of Cell Biology, 218(11), 3827–3844. https://doi.org/10.1083/jcb.201904051
Frey, W. D., Anderson, A. Y., Lee, H., Nguyen, J. B., Cowles, E. L., Lu, H., et al. (2022). Phosphoinositide species and filamentous actin formation mediate engulfment by senescent tumor cells. PLoS Biol, 20(10), e3001858. https://doi.org/10.1371/journal.pbio.3001858
Patel, N. H., Sohal, S. S., Manjili, M. H., Harrell, J. C., & Gewirtz, D. A. (2020). The Roles of Autophagy and Senescence in the Tumor Cell Response to Radiation. Radiation Research, 194(2), 103–115. https://doi.org/10.1667/RADE-20-00009
Behmoaras, J., & Gil, J. (2021). Similarities and interplay between senescent cells and macrophages. J Cell Biol, 220(2), https://doi.org/10.1083/jcb.202010162.
Rodier, F. (2013). Detection of the senescence-associated secretory phenotype (SASP). Methods in Molecular Biology, 965, 165–173. https://doi.org/10.1007/978-1-62703-239-1_10
Takasugi, M., Yoshida, Y., Hara, E., & Ohtani, N. (2022). The role of cellular senescence and SASP in tumour microenvironment. The FEBS Journal, febs.16381, https://doi.org/10.1111/febs.16381.
Krtolica, A., Parrinello, S., Lockett, S., Desprez, P. Y., & Campisi, J. (2001). Senescent fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging. Proc Natl Acad Sci U S A, 98(21), 12072–12077. https://doi.org/10.1073/pnas.211053698211053698[pii]
Coppe, J. P., Desprez, P. Y., Krtolica, A., & Campisi, J. (2010). The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol, 5, 99–118. https://doi.org/10.1146/annurev-pathol-121808-102144
留言 (0)